Aspirin Discontinuation and Preterm Preeclampsia

A randomized clinical trial has shown that discontinuing aspirin at 24 to 28 weeks of gestation in pregnant individuals at high risk for preterm preeclampsia can be a safe and effective strategy. The study found that aspirin significantly reduced the incidence of preterm preeclampsia by 62%, with aspirin discontinuation showing a comparable incidence rate to those who continued taking it. With 936 participants, the trial utilized specific biophysical and molecular factors to better identify candidates at heightened risk in their first trimester. The findings suggest reassessment of existing guidelines to improve risk stratification and potentially enhance maternal and neonatal outcomes through more personalized care approaches.